Siegfried Holding AG
SIX:SFZN

Watchlist Manager
Siegfried Holding AG Logo
Siegfried Holding AG
SIX:SFZN
Watchlist
Price: 1 114 CHF 0.91% Market Closed
Market Cap: 4.8B CHF
Have any thoughts about
Siegfried Holding AG?
Write Note

Siegfried Holding AG
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Siegfried Holding AG
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Siegfried Holding AG
SIX:SFZN
Total Receivables
CHf361.5m
CAGR 3-Years
17%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Bachem Holding AG
SIX:BANB
Total Receivables
CHf148.2m
CAGR 3-Years
23%
CAGR 5-Years
18%
CAGR 10-Years
16%
Lonza Group AG
SIX:LONN
Total Receivables
CHf1.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Tecan Group AG
SIX:TECN
Total Receivables
CHf206.4m
CAGR 3-Years
16%
CAGR 5-Years
11%
CAGR 10-Years
N/A
PolyPeptide Group AG
SIX:PPGN
Total Receivables
€96m
CAGR 3-Years
14%
CAGR 5-Years
14%
CAGR 10-Years
N/A
SKAN Group AG
SIX:SKAN
Total Receivables
CHf38.4m
CAGR 3-Years
9%
CAGR 5-Years
389%
CAGR 10-Years
N/A
No Stocks Found

Siegfried Holding AG
Glance View

Market Cap
4.8B CHF
Industry
Life Sciences Tools & Services

Siegfried Holding AG engages in the development and manufacture of active pharmaceutical ingredients for pharmaceutical clients with research and development programs, related intermediates, and controlled substances. The company is headquartered in Zofingen, Aargau and currently employs 3,432 full-time employees. The firm produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and steriles. The firm's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The firm operates production facilities in Switzerland, Germany, France, Malta, the United States and China.

SFZN Intrinsic Value
1 192.72 CHF
Undervaluation 7%
Intrinsic Value
Price

See Also

What is Siegfried Holding AG's Total Receivables?
Total Receivables
361.5m CHF

Based on the financial report for Jun 30, 2024, Siegfried Holding AG's Total Receivables amounts to 361.5m CHF.

What is Siegfried Holding AG's Total Receivables growth rate?
Total Receivables CAGR 5Y
14%

Over the last year, the Total Receivables growth was 11%. The average annual Total Receivables growth rates for Siegfried Holding AG have been 17% over the past three years , 14% over the past five years .

Back to Top